1 |
Gupta P, Sharma PK, Mir H, et al (2014). CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget, 5, 10170-9.
DOI
|
2 |
Li J, Jiang K, Qiu X, et al (2014). Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep, 47, 33-8.
DOI
|
3 |
Liu BL, Liu SJ, Baskys A, et al (2014). Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer. BMC Cancer, 14, 829.
DOI
|
4 |
Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al (2014). CXCR4 expression enhances diffuse large B-cell lymphoma dissemination and decreases patient survival. J Pathol, [Epub ahead of print].
|
5 |
Nakata B, Fukunaga S, Noda E, et al (2008). Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology, 74, 69-75.
DOI
|
6 |
Oliver JA, Ortiz R, Melguizo C, et al (2014). Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer, 14, 511.
DOI
|
7 |
Tan Y, Chen B, Xu W, et al (2014). Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol, 2, 111-5.
|
8 |
Wang N, Luo HJ, Yin GB, et al (2013). Overexpression of HIF- , TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma. Clin Dev Immunol, 2013, 589423.
|
9 |
Wu J, Wu X, Liang W, et al (2014). Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a metaanalysis. Tumour Biol, 35, 3709-15.
DOI
|
10 |
Wang W, Chen Y, Deng J, et al (2014). The prognostic value of CD133 expression in non-small cell lung cancer: a metaanalysis. Tumour Biol, 35, 9769-75.
DOI
|
11 |
Wu H, Qi XW, Yan GN, et al (2014). Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS One, 9, 100168.
DOI
|
12 |
Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4.
DOI
|
13 |
Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22.
DOI
ScienceOn
|
14 |
Xu CZ, Wang PH, Yan XJ, et al (2013). Expression of CXCR4 is associated with progression and invasion in patients with nasal-surface basal cell carcinoma. J Otorhinolaryngol Relat Spec, 75, 332-41.
DOI
|
15 |
Yao Q, Sun JG, Ma H, et al (2014). Monitoring microRNAs using a molecular beacon in CD133+/ CD338+ human lung adenocarcinoma-initiating A549 cells. Asian Pac J Cancer Prev, 15, 161-6.
DOI
ScienceOn
|
16 |
Yang L, Huang XE, Xu L, et al (2013). Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study. Asian Pac J Cancer Prev, 14, 6403-9.
DOI
ScienceOn
|
17 |
Yu S, Wang X, Liu G, et al (2013). High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. Acta Med Okayama, 67, 369-75.
|
18 |
Zhang Z, Ni C, Chen W, et al (2014). Expression of CXCR4 and breast cancer prognosis: a systematic review and metaanalysis. BMC Cancer, 14, 49.
DOI
|
19 |
Zheng NG, Mo SJ, Li JP, et al (2014). Anti-CSC effects in human esophageal squamous cell carcinomas and Eca109/9706 cells induced by nanoliposomal quercetin alone or combined with CD 133 antiserum. Asian Pac J Cancer Prev, 15, 8679-84.
DOI
|
20 |
Zhai JH, Gu WC, Xu XL, et al (2014). Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis. Tumour Biol, [Epub ahead of print].
|
21 |
Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Cancer Prev, 15, 707-12.
DOI
ScienceOn
|
22 |
Bahnassy AA, Fawzy M, El-Wakil M, et al (2014). Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res, [Epub ahead of print].
|
23 |
Chen S, Song X, Chen Z, et al (2013). CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One, 8, 56380.
DOI
|
24 |
Chen K, Li Z, Jiang P, et al (2014). Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncol Rep, 32, 755-63.
|